On Nov. 14, the FDA approved first-time merchandise formulations of azithromycin 250-, 500-, and 600-mg tablets (made by Teva Pharmaceuticals USA and Sandoz, Inc; brand name name Zithromax, made by Pfizer, Inc).
Azithromycin tablets are indicated for the aid of adults with mild to moderate infections caused by susceptible strains of designated microorganisms.
Medicament indications for the 250-and 500-mg in adults include acute bacterial exacerbations of chronic obstructive pulmonary disease, acute bacterial sinusitis, community-acquired pneumonia (CAP), pharyngitis/tonsillitis, uncomplicated skin/skin bodily structure infections, urethritis, cervicitis, and genital ulcer disease (men only). The tablets may also be used to delicacy acute otitis media, CAP, and pharyngitis/tonsillitis in pediatric patients.
Azithromycin 600-mg tablets are indicated for the communication of acute bacterial exacerbations of chronic obstructive pulmonary disease, CAP, pharyngitis/tonsillitis, uncomplicated skin/skin artifact infections, and non-gonococcal urethritis/cervicitis. They are also indicated for the prophylaxis and intervention of disseminated Mycobacterium avium composite (MAC) disease.